Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pioglitazone/metformin - Takeda

Next Previous
X
Search
Drug Profile

Pioglitazone/metformin - Takeda

Alternative Names: ACTOplus met; ACTOplus met XR; AD 48833MET; Competact; Glubrava; Metact; Metformin/pioglitazone - Takeda; Metformin/pioglitazone XR

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda; Takeda Pharmaceuticals North America
  • Developer Takeda; Takeda Pharmaceuticals USA
  • Class Antihyperglycaemics; Biguanides; Small molecules; Thiazolidinediones
  • Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 11 Feb 2019 Pioglitazone/metformin is not yet available in Iceland and Liechtenstein for the treatment of Type 2 diabetes mellitus
  • 25 Jan 2019 Chemical structure information added
  • 30 Apr 2015 Launched for Type-2 diabetes mellitus in Greece and Austria (PO) before April 2015

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top